CME credits: 1.00

Valid until: 06-09-2023

Claim your CME credit at https://reachmd.com/programs/cme/sars-cov-2-variants/13442/

Like other viruses, SARS-CoV-2 evolves over time. Certain variants have gained widespread attention because of their rapid emergence within populations and evidence for transmission or clinical implications; per the CDC, these are considered variants of concern. Clinicians may be challenged to optimize use of COVID-19 vaccines and therapeutics in the clinical context of SARS-CoV-2 variants given the complex nature of the variants and the ever-evolving data surrounding them. Because of the significance associated with SARS-CoV-2 variants, clinicians require education on the latest data and clinical recommendations regarding these variants.

Disclaimer: This accredited CE activity is valid and scientifically evidence based as of the date of recording.

=

CME credits: 1.00

Valid until: 06-09-2023

Claim your CME credit at https://reachmd.com/programs/cme/treatments-for-outpatients-with-mild-to-moderate-covid-19/13441/

Normal functions of the immune system include defense against infections. As the immune system ages and these capabilities decline, however, there is increased susceptibility to infections. Individuals of any age can acquire SARS-CoV-2 infection, although adults of middle age and older are most commonly affected, and older adults are more likely to have severe disease. Older age is also associated with increased COVID-19-related mortality. There is a need for knowledge regarding the harmful effects of the aging immune system (immunosenescence) and the role of chronic inflammation among elderly populations to facilitate enhanced clinical monitoring of at-risk patients. As such, an educational activity is needed to provide up-to-date coverage of the knowledge regarding immunosenescence in the context of COVID-19 to help optimize patient outcomes.

Disclaimer: This accredited CE activity is valid and scientifically evidence based as of the date of recording.

=

CME credits: 1.00

Valid until: 06-09-2023

Claim your CME credit at https://reachmd.com/programs/cme/immunosenescence-and-inflammaging-role-of-aging-as-a-risk-factor-for-severe-covid-19/13440/

Our understanding of the spectrum of COVID-19 as well as optimal management tactics continue to develop. In light of the ever-changing data and clinical recommendations surrounding COVID-19, clinicians are challenged to stay abreast of current treatment-related information with the potential to impact clinical decision-making. To mitigate the overall health burden associated with this devastating pandemic, healthcare professionals must be up to date on the latest practice-changing information regarding recommended therapeutic strategies, which include monoclonal antibodies, for high-risk patients in the outpatient setting. As such, an educational initiative surrounding COVID-19 outpatient treatments is warranted.

Disclaimer: This accredited CE activity is valid and scientifically evidence based as of the date of recording.

=

CME credits: 1.00

Valid until: 30-08-2023

Claim your CME credit at https://reachmd.com/programs/cme/harnessing-the-power-of-the-immune-system-to-manage-higher-risk-mds/13787/

Myelodysplastic syndrome (MDS) is a group of myeloid malignancies characterized by ineffective hematopoiesis, inflammation, and immune dysregulation in the setting of multiple genomic disruptions. Disease burdens associated with MDS encompass complications of the disease itself as well as those associated with transformation to acute myeloid leukemia (AML). Patients with high-risk MDS (HR-MDS) face even greater challenges, particularly when treated in community-based settings. This risk stems from the presence of greater numbers of cytogenetic abnormalities, which are unstable and associated with increased transformation to AML. Patients with HR-MDS and AML may not be candidates for allogeneic stem hematopoietic cell transplantation due to age or comorbidities. Hypomethylating agents (HMAs) remain as the standard of care for HR-MDS; however, responses to HMA do not exceed 50% and are short-lived. The efficacy of HMAs in some patients with MDS and their long-standing role in therapy have led to the development of novel treatment approaches that make use of HMA combination therapies with immune-based therapies, such as those that target the TIM-3 pathway.

This educational activity will focus on assessing MDS risk and its relation to treatment choices, the rationale and mechanism of action for novel immune-based therapies and integrating emerging combination therapies into clinical …=

CME credits: 1.00

Valid until: 30-08-2023

Claim your CME credit at https://reachmd.com/programs/cme/shifting-paradigms-for-assessment-and-management-of-lower-risk-myelodysplastic-syndromes-genomics-risk-stratification-and-novel-therapies/13788/

Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms associated with cytopenias, suboptimal production of mature erythrocytes, and substantial risk for progression to acute myeloid leukemia.

The classification of MDS and MDS/myeloproliferative neoplasm (MPN) overlap syndromes continue to evolve, making them difficult for clinicians to define and raising important new considerations for diagnosis, assessment, risk stratification, and treatment. The presence of ring sideroblasts (RS) and mutations in the SF3B1 gene correlate with favorable outcomes and help define specific disease subtypes.

In this video-based educational activity, an interview-style expert faculty panel will provide their perspectives and insights on the latest trends and emerging research in low-risk MDS, including guideline-directed diagnostic workup, RS evaluation and SF3B1 testing and their implications, currently approved and novel emerging treatment strategies for managing lower risk MDS, and strategies to mitigate and manage treatment-related adverse events.

=

CME credits: 1.00

Valid until: 31-08-2023

Claim your CME credit at https://reachmd.com/programs/cme/improved-outcomes-in-mcrpc-with-psma-directed-diagnostics-and-therapies/13789/

Prostate-specific membrane antigen (PSMA) is highly expressed on prostate cancer (PC) cells and can be detected in tumors using positron emission tomography imaging. Even though clinical features predict different stages of PC progression, the application of imaging to guide treatment is still evolving but gaining substantial evidence for the targeting of PSMA. With clinical research shifting paradigms for the treatment of metastatic castration-resistant prostate cancer (mCRPC), novel treatment options require adoption and effective application into clinical practice. PSMA has become an appealing target for diagnostic agents for imaging and therapeutic agents to treat mCRPC. Radionuclide emitters are being used for both cell surface expression of PSMA and the tumor microenvironment, and research has proven the therapeutic efficacy of PSMA-directed radioligand therapy (RLT).

In this educational activity, two experts will examine the role and rationale for PSMA targeted therapies and diagnostics—jointly known as theragnostics—as a revolutionary new approach to treating patients with advanced prostate cancer and will evaluate clinical trial data for PSMA-targeted RLT.

=

CME credits: 1.00

Valid until: 31-08-2023

Claim your CME credit at https://reachmd.com/programs/cme/sleuthing-unexplained-dyspnea-diagnostic-tools/13719/

Unexplained dyspnea may have many causes, which is why patients must have a complete diagnostic work-up to rule out pulmonary hypertension (PH) as a root cause. The differential diagnosis of PH is multifaceted and should be a collaborative effort between the community healthcare provider and the PH specialist at the PH center. Many diagnostic evaluations may be performed outside of the PH center, but right heart catheterization, which is the definitive procedure, and adjoining tests should be performed at the center. Newer and emerging diagnostic imaging techniques may also prove helpful, particularly in diagnosing chronic thromboembolism leading to chronic thromboembolic pulmonary hypertension. This program reviews the diagnostic approach to determining whether PH is the root cause of patients’ dyspnea and considers when community physicians, having created an index of suspicion for PH, should immediately refer their patients to the PH center for a full work-up.

CME credits: 1.50

Valid until: 30-08-2023

Claim your CME credit at https://reachmd.com/programs/cme/mezigdomide-cc-92480-a-potent-novel-cereblon-e3-ligase-modulator-combined-with-dexamethasone-in-patients-with-relapsedrefractory-multiple-myeloma-preliminary-results-from-the-dose-expansion-phase-of-the-cc-92480-mm-001-trial/14335/

With the introduction of both immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide, and the use of these in combination with drugs from other classes, IMiDs have made a dramatic progress in the treatment of multiple myeloma (MM). However, despite improvement in outcomes, patients with MM ultimately relapse and must undergo further treatment. Early studies show that Cereblon E3 Ligase Modulators (CELMoDs®) iberdomide and CC-92480 show similar trends in activity in patients refractory to IMiDs. This new next generation of IMIDs have shown enhanced tumoricidal and immune-stimulatory effects compared with first-generation IMiDs and have the potential to replace the current standard of care in both frontline and RRMM. This program covers the benefits as well as current challenges with the use of first-generation IMiDs while exploring the MOA, clinical, and safety activity to date of selective CELMoD® therapy in MM.

CME credits: 1.50

Valid until: 30-08-2023

Claim your CME credit at https://reachmd.com/programs/cme/panel-how-do-we-address-the-unmet-needs-in-mm-with-existing-immunomodulatory-agents/14326/

With the introduction of both immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide, and the use of these in combination with drugs from other classes, IMiDs have made a dramatic progress in the treatment of multiple myeloma (MM). However, despite improvement in outcomes, patients with MM ultimately relapse and must undergo further treatment. Early studies show that Cereblon E3 Ligase Modulators (CELMoDs®) iberdomide and CC-92480 show similar trends in activity in patients refractory to IMiDs. This new next generation of IMIDs have shown enhanced tumoricidal and immune-stimulatory effects compared with first-generation IMiDs and have the potential to replace the current standard of care in both frontline and RRMM. This program covers the benefits as well as current challenges with the use of first-generation IMiDs while exploring the MOA, clinical, and safety activity to date of selective CELMoD® therapy in MM.

CME credits: 1.50

Valid until: 30-08-2023

Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-importance-of-cereblon-to-the-mechanism-of-action-of-immunomodulatory-drugs-and-celmods-in-mm/14327/

With the introduction of both immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide, and the use of these in combination with drugs from other classes, IMiDs have made a dramatic progress in the treatment of multiple myeloma (MM). However, despite improvement in outcomes, patients with MM ultimately relapse and must undergo further treatment. Early studies show that Cereblon E3 Ligase Modulators (CELMoDs®) iberdomide and CC-92480 show similar trends in activity in patients refractory to IMiDs. This new next generation of IMIDs have shown enhanced tumoricidal and immune-stimulatory effects compared with first-generation IMiDs and have the potential to replace the current standard of care in both frontline and RRMM. This program covers the benefits as well as current challenges with the use of first-generation IMiDs while exploring the MOA, clinical, and safety activity to date of selective CELMoD® therapy in MM.